Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 01, 2023 16:05 ET | Source: Oncorus, Inc.

Oncorus Announces Workforce Reduction Plan

ANDOVER, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes...
May 22, 2023 16:05 ET | Source: Oncorus, Inc.

Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates

IND submission for ONCR-021 still planned for mid-2023, subject to receipt of additional funding Ended the quarter with $45.0 million in cash, cash equivalents and investments ANDOVER, Mass., May ...
March 24, 2023 07:00 ET | Source: Oncorus, Inc.

Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Reprioritized product portfolio to focus on IV-administered, self-amplifying RNA medicinesOn track to submit IND for ONCR-021 in mid-2023Preclinical data featured in Nature Communications support...
January 04, 2023 07:00 ET | Source: Oncorus, Inc.

Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates

Research collaboration leverages Oncorus’ proprietary ionizable amines, PEG lipids, LNP formulations, process development and manufacturing together with Daewoong’s mRNA expertiseOpportunity for...
November 30, 2022 07:00 ET | Source: Oncorus, Inc.

Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer

Company now focused on the development of ONCR-021, Oncorus’ lead self-amplifying RNA product candidate for non-small cell lung and other cancers; program remains on track for IND submission in...
November 23, 2022 08:00 ET | Source: Oncorus, Inc.

Oncorus to Participate in Upcoming Investor Conferences

ANDOVER, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today...
November 18, 2022 08:00 ET | Source: Oncorus, Inc.

Oncorus Presents Preclinical Data Supporting ONCR-719, an armed HSV-1 Vector engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry in Glioblastoma, at the 2022 Society for Neuro-Oncology Annual Meeting

ONCR-719 is uniquely engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry, which is highly expressed in glioblastoma multiforme (GBM); data show that the canonical...
November 02, 2022 07:00 ET | Source: Oncorus, Inc.

Oncorus Reports Third Quarter 2022 Financial Results and Provides Business Updates

Additional clinical data from ONCR-177 surface lesion monotherapy and combination expansion cohorts expected in the fourth quarter of 2022On track to submit IND for ONCR-021 in mid-2023Completed...
October 07, 2022 09:00 ET | Source: Oncorus, Inc.

Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer

ANDOVER, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on stimulating the immune system to transform outcomes for cancer patients,...
September 26, 2022 07:00 ET | Source: Oncorus, Inc.

Oncorus to Present at Chardan’s 6th Annual Genetic Medicines Conference

ANDOVER, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today...